Development and validation of an interpretable prehospital return of spontaneous circulation (P-ROSC) score for patients with out-of-hospital cardiac arrest using machine learning: A retrospective study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 35706500.
- Also identified by DOI 10.1016/j.eclinm.2022.101422 and PMC identifier 9096672.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Return of spontaneous circulation (ROSC) before arrival at the emergency department is an early indicator of successful resuscitation in out-of-hospital cardiac arrest (OHCA). Several ROSC prediction scores have been developed with European cohorts, with unclear applicability in Asian settings. We aimed to develop an interpretable prehospital ROSC (P-ROSC) score for ROSC prediction based on patients with OHCA in Asia. This retrospective study examined patients who suffered from OHCA between Jan 1, 2009 and Jun 17, 2018 using data recorded in the Pan-Asian Resuscitation Outcomes Study (PAROS) registry. AutoScore, an interpretable machine learning framework, was used to develop P-ROSC. On the same cohort, the P-ROSC was compared with two clinical scores, the RACA and the UB-ROSC. The predictive power was evaluated using the area under the curve (AUC) in the receiver operating characteristic analysis. 170,678 cases were included, of which 14,104 (8.26%) attained prehospital ROSC. The P-ROSC score identified a new variable, prehospital drug administration, which was not included in the RACA score or the UB-ROSC score. Using only five variables, the P-ROSC score achieved an AUC of 0.806 (95% confidence interval [CI] 0.799-0.814), outperforming both RACA and UB-ROSC with AUCs of 0.773 (95% CI 0.765-0.782) and 0.728 (95% CI 0.718-0.738), respectively. The P-ROSC score is a practical and easily interpreted tool for predicting the probability of prehospital ROSC. This research received funding from SingHealth Duke-NUS ACP Programme Funding (15/FY2020/P2/06-A79).